Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.76 |
| ▸ | EGFR | P00533 | 5/20 | 0.76 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.48 |
| ▸ | FECH | P22830 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.48 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565580 | 1.00 | ERBB2 (1.00) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5567338 | 0.95 | ERBB2 (0.91) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5570017 | 0.93 | ERBB2 (0.87) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5567173 | 0.92 | ERBB2 (0.86) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5568831 | 0.92 | ERBB2 (0.86) | ERBB2KCNH2EGFRMKNK2 | |
| SCHEMBL5634776 | 0.92 | ERBB2 (0.85) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5635711 | 0.92 | ERBB2 (0.85) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5569953 | 0.92 | ERBB2 (0.85) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5570427 | 0.91 | ERBB2 (0.84) | ERBB2KCNH2EGFRERBB3ERBB4 | |
| SCHEMBL5569868 | 0.91 | ERBB2 (0.83) | ERBB2KCNH2EGFRERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | claimed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885KCNH2 2481/4885EGFR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.